Want to see IN:NEULANDLAB full AI Analyst Report?
NEULANDLAB Stock Chart & Stats
₹18570.85
₹448.00(2.42%)
At close: 4:00 PM EDT
₹18570.85
₹448.00(2.42%)
Day’s Range― - ―
52-Week Range₹11,500.00 - ₹20,072.00
Previous CloseN/A
Volume27.75K
Average Volume (3M)2.41K
Market Cap
₹244.64B
Enterprise Value₹153.58K
Total Cash (Recent Filing)₹3.55B
Total Debt (Recent Filing)₹3.01B
Price to Earnings (P/E)67.1
Beta1.19
Next Earnings
Aug 05, 2026EPS Estimate
60.01Next Dividend Ex-DateN/A
Dividend Yield0.18%
Share Statistics
EPS (TTM)283.70
Shares Outstanding12,829,889
10 Day Avg. Volume1,318
30 Day Avg. Volume2,408
Financial Highlights & Ratios
PEG Ratio1.06
Price to Book (P/B)8.23
Price to Sales (P/S)7.63
P/FCF Ratio-262.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)326.8
Revenue Forecast (FY)₹23.09B
Bulls Say, Bears Say
Bulls Say
Sustained ProfitabilityConsistently healthy net and EBIT margins indicate durable economics and pricing power in API manufacturing. Strong operating profitability supports reinvestment, sustained return on equity, and the ability to fund growth or weather cyclical pressures in the pharmaceutical supply chain.
Conservative Balance SheetLow leverage and steadily growing equity provide financial flexibility and a buffer against shocks. Conservative capital structure supports investment in capacity or R&D, helps secure customer contracts that require regulatory investments, and lowers solvency risk over the medium term.
API / CDMO Business Model & Revenue GrowthFocus on complex APIs and contract development/manufacturing targets structural demand from innovator and generic drug makers. Strong historical revenue growth reflects market traction and the stickiness of qualified supplier status, supporting recurring revenue and mid-term visibility.
Bears Say
Weak Free Cash FlowNegative free cash flow in FY2026 despite reported profits signals either higher capex or working capital strain. Persistent FCF weakness would reduce the company's ability to self-fund investments, repay debt, or return capital, increasing reliance on external financing.
Margin CompressionA sharp decline in gross margin points to rising input costs or adverse product mix. Margin erosion undermines operating leverage and could materially lower sustainable profitability and ROE unless costs are controlled or pricing is adjusted without losing customers.
Rising Absolute DebtAlthough leverage ratios remain low, higher nominal debt in FY2026 reduces headroom and increases fixed obligations. This curtails financial flexibility precisely when cash conversion weakened and margins compressed, raising medium-term refinancing and liquidity risk.
Neuland Laboratories Ltd. News
NEULANDLAB FAQ
What was Neuland Laboratories Ltd.’s price range in the past 12 months?
Neuland Laboratories Ltd. lowest stock price was ₹11500.00 and its highest was ₹20072.00 in the past 12 months.
What is Neuland Laboratories Ltd.’s market cap?
Neuland Laboratories Ltd.’s market cap is ₹244.64B.
When is Neuland Laboratories Ltd.’s upcoming earnings report date?
Neuland Laboratories Ltd.’s upcoming earnings report date is Aug 05, 2026 which is in 2 days.
How were Neuland Laboratories Ltd.’s earnings last quarter?
Neuland Laboratories Ltd. released its earnings results on May 12, 2026. The company reported ₹165.76 earnings per share for the quarter, beating the consensus estimate of ₹78.16 by ₹87.6.
Is Neuland Laboratories Ltd. overvalued?
According to Wall Street analysts Neuland Laboratories Ltd.’s price is currently Overvalued.
Does Neuland Laboratories Ltd. pay dividends?
Neuland Laboratories Ltd. pays a Annually dividend of ₹34 which represents an annual dividend yield of 0.18%. See more information on Neuland Laboratories Ltd. dividends here
What is Neuland Laboratories Ltd.’s EPS estimate?
Neuland Laboratories Ltd.’s EPS estimate is 60.01.
How many shares outstanding does Neuland Laboratories Ltd. have?
Neuland Laboratories Ltd. has 12,829,889 shares outstanding.
What happened to Neuland Laboratories Ltd.’s price movement after its last earnings report?
Neuland Laboratories Ltd. reported an EPS of ₹165.76 in its last earnings report, beating expectations of ₹78.16. Following the earnings report the stock price went down -3.121%.
Which hedge fund is a major shareholder of Neuland Laboratories Ltd.?
Currently, no hedge funds are holding shares in IN:NEULANDLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Neuland Laboratories Ltd.
Neuland Laboratories Ltd. operates as a global developer and supplier of active pharmaceutical ingredients (APIs), distributing its products across India, Europe, the United States, and other international markets. These APIs are crucial components in treatments spanning a wide array of therapeutic areas, such as respiratory conditions (antiasthmatics), cardiovascular health, fungal infections, seizure control (anticonvulsants), central nervous system disorders, bacterial infections (fluoroquinolones, antibacterial), mental health (antipsychotic), and Parkinson's disease. Additionally, the company provides bespoke manufacturing solutions and specialized peptide synthesis services. Founded in 1984, Neuland Laboratories is headquartered in Hyderabad, India.
Technical Analysis
Aurobindo Pharma Ltd
―
Divi's Laboratories Limited
―
Glenmark Life Sciences Limited
―
Granules India Limited
―
Laurus Labs Ltd.
―